Pulmonary Hypertension

September 30, 2015November 5, 2015

Bellerophon Reveals Positive Data on INOpulse Inhaled Nitric Oxide Therapy for Pulmonary Arterial Hypertension-Associated COPD

On September 30, Bellerophon Therapeutics published results from clinical trials performed for investigational therapy INOpulse® on patients with pulmonary arterial hypertension (PAH) associated with chronic obstructive pulmonary disease (COPD). The results were ... Read more

September 30, 2015November 5, 2015

Calcilytics Explored as Potential Drug Candidates for Pulmonary Arterial Hypertension Treatment

News, Pulmonary Hypertension

In a paper recently published in the PLOS ONE journal entitled “Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension,” researchers from Kinjo Gakuin University in Japan demonstrated ... Read more

September 28, 2015November 5, 2015

Bellerophon Makes Two Important Announcements For Pulmonary Arterial Hypertension Therapy Program INOpulse

News, Pulmonary Hypertension

Last week, Bellerophon Therapeutics, Inc., (Nasdaq:BLPH), a clinical-stage biotherapeutics company focused on developing therapies that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases, made two ... Read more

September 28, 2015November 5, 2015

PAH Genetic Risk Factors Collected in New, Comprehensive Database Could Improve Diagnosis, Treatment Decisions

News, Pulmonary Hypertension

Known genetic risk factors associated with PAH (Pulmonary Arterial Hypertension) have been organized and assembled by researchers in an updated compilation, freely available on the public repository ClinVar. This important new ... Read more

September 24, 2015November 5, 2015

Clinical Trial Data On PH Therapy Selexipag (Uptravi) & Macitentan (Opsumit) To Be Presented At European Respiratory Society Congress

News, Pulmonary Hypertension

Actelion BioPharmaceuticals recently announced that the company will be releasing important data from its Phase III GRIPHON study testing the efficacy and tolerability of their pipeline drug selexipag (Uptravi®) for the treatment ... Read more

September 22, 2015November 5, 2015

Mosaic Pattern of Lung Attenuation on Chest CT Scans Detected in Some Pulmonary Hypertension Patients

News, Pulmonary Hypertension

A new study identified a mosaic pattern of lung attenuation on chest CT scans detected in some Pulmonary Hypertension patients, particularly those patients with CTEPH. The study, entitled “Mosaic Pattern of ... Read more

September 21, 2015November 5, 2015

Study Reveals Risk Factors for Pulmonary Hypertension in Sickle Cell Patients

News, Pulmonary Hypertension

A study in PLoS One entitled “Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia” published September 3, 2015 and authored by Clarisse Lopes de Castro Lobo, et. ... Read more

September 18, 2015November 5, 2015

PHA Symposium Aims to Promote Cross-functional Knowledge Exchange on PH Treatments

News, Pulmonary Hypertension

The Pulmonary Hypertension Association (PHA) is hosting the 2015 PH Professional Network (PHPN) Symposium, which began on Thursday, September 17 and will run until Saturday, September 19 at the Crystal Gateway ... Read more

September 16, 2015November 5, 2015

Lung Transplant Rejection Reduced By New Filtering Technique

News, Pulmonary Hypertension

A new technique called lung filtering may offer hope for end-stage lung disease patients in need of a lung transplant. According to researchers from the University of Manchester, which is cooperating ... Read more

September 16, 2015November 5, 2015

Reata Announces Presentation of Initial Phase 2 Data on Bardoxolone Methyl for PAH at 2015 CHEST Meeting

News, Pulmonary Hypertension

Irving, Texas-based Reata Pharmaceuticals, Inc, recently announced that it will present initial data evaluating bardoxolone methyl in patients with pulmonary arterial hypertension (PAH) who are on stable background therapy during the 2015 ... Read more